Products - Diabetes | Topic | NICE

Showing 25 products

Date | Sort by Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Sotagliflozin with insulin for treating type 1 diabetes (TA622)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
12 February 2020
Dapagliflozin with insulin for treating type 1 diabetes (TA597)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
12 February 2020
Published date:
28 August 2019
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
20 November 2019
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
5 June 2019
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
27 March 2019
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
23 November 2016
Published date:
26 June 2013
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
23 November 2016
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
25 May 2016
Aflibercept for treating diabetic macular oedema (TA346)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
22 July 2015
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
22 July 2015
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
25 March 2015
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
25 June 2014
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
27 November 2013
Ranibizumab for treating diabetic macular oedema (TA274)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
27 February 2013
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
23 July 2008
Diabetic retinopathy - ruboxistaurin [ID382]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macular oedema (diabetic) - pegaptanib sodium [ID452]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Diabetes - buccal insulin [ID311]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Semaglutide for treating type 2 diabetes (ID1450)
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dulaglutide for treating type 2 diabetes [ID1451]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ranibizumab for treating diabetic retinopathy [ID1592]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC